MacuSight names new vice president of operations

At MacuSight, Mr Wroblewski will be responsible for overseeing functions related to each of these areas of expertise to support the company’s broad Phase II clinical development program for its lead drug candidate, sirolimus.

Prior to joining MacuSight, Mr Wroblewski served as COO at iScience Interventional, a start-up medical device company in the ophthalmology space.

MacuSight is currently developing its proprietary sirolimus product for the treatment of diabetic macular edema, wet age-related macular degeneration, and other target ophthalmic indications.

David Weber, president and CEO of MacuSight, said: “We are fortunate to have brought aboard an individual with Jerry’s breadth of relevant experience in the important areas of manufacturing, product supply chain management and quality assurance.

“Having worked alongside Jerry previously, I know that his contributions at MacuSight will help solidify our manufacturing capability to ensure that all facets of our sirolimus development program are strong as we continue to advance this important drug candidate toward the market.”